@misc{oai:repo.qst.go.jp:00070279,
 author = {Tanimoto, Katsuyuki and Yoshikawa, Kyosan and Shiraishi, Takahiro and Toubaru, Sachiko and Ohashi, Seiya and Saga, Tsuneo and Watanabe, Kazuhiro and Kamada, Tadashi and Miyazaki, Masaru and et.al and 谷本 克之 and 吉川 京燦 and 白石 貴博 and 桃原 幸子 and 大橋 靖也 and 佐賀 恒夫 and 渡邊 和洋 and 鎌田 正 and 宮崎 勝},
 month = {Oct},
 note = {ObjectivesFDG-PET provides quantitative information regarding the tumor glucosemetabolism which is useful for the clinical diagnosis of tumor diseases. Adiffusion weighted image (DWI) by MRI can be useful in detecting malignanciessimilar to FDG-PET imaging. We evaluated the role of the clinical use ofFDG-PET/CT and DWI by MRI in the differential diagnosis of tumor malignancywith suspected pancreatic cancer, and in the prediction of tumor recurrence forpancreatic cancer. Materials and Methods Pre-surgery patients with eitherproven or suspected primary pancreatic cancer underwent a whole body FDG-PET/CTand DWI by MRI. The malignancy or benignancy of excised specimens waspathologically confirmed in all cases. The tumor glucose metabolism wasevaluated with standardized uptake value (SUV) in FDG-PET/CT (Aquiduo; Toshiba)study. After at least 6hours of fasting, each patient was injected with FDG(217.8-372.5MBq, average: 321.6MBq ) 60 min before imaging. DWI acquired with a3.0-T MRI scanner (Signa HDx 3T; GE Healthcare) with an 8 channel TORSO arraycoil (8US TORSOPA). The apparent diffusion coefficient (ADC) were measured withDWI using a spin echo echo-planar sequence, TR=10s; TE=80 ms; b value=400, 800,1200s/mm2. We obtained SUV from the FDG injected dose and patientbody weight, and ADC from DWI with three types of b values. ADC was calculatedusing the Advantage work station 4.2; fanctool2, GE Healthcare, and we used theaverage values for ADC value. The value of each factor for differentialdiagnosis of tumor malignancy was determined by analysis of the area under thereceiver operating characteristic (ROC) curve with suspected pancreatic cancer.Similarly, the predictive value of each factor for 1-year tumor recurrence wasdetermined by analysis of the area under the ROC curve with proven pancreaticcancer. Results On ROC curve analysis for differential diagnosis of tumormalignancy, the areas under the curve of SUV and ADC were 0.855 and 0.830,respectively. On ROC curve analysis for tumor recurrence, the areas under thecurve of SUV and ADC were 0.843 and 0.600, respectively. The 1-year recurrencefree survival rate above the cutoff (SUV>4.3) was markedly different fromthe rate below the cutoff (SUV&#8804;4.3) (100% vs. 67%, p<0.01). ConclusionsFDG-PET/CT and ADC from MRI are helpful in differential diagnosis of tumormalignancy. FDG-PET/CT should be performed in preoperative evaluation ofpancreatic tumor not only for differential diagnosis of tumor malignancy butalso for prediction of tumor recurrence., The 2010 EANM Congress},
 title = {Prediction of tumor recurrence by FDG-PET/CT and MRI for pancreatic cancer},
 year = {2010}
}